NCT06846736View on ClinicalTrials.gov

ALK Digital Pathology Outcome Predition, Multi Institutional, Restrospective Study

Enrolling by invitationOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

August 13, 2023

Primary Completion Date

December 1, 2027

Study Completion Date

December 1, 2028

Conditions
Alk-positive Non-Small Cell Lung CancerALK-inhibitor Treated
Trial Locations (1)

5262000

Sheba Medical Center, Ramat Gan

Sponsors

Collaborators (1)

Mayo Clinic
All Listed Sponsors
collaborator

Mayo Clinic

OTHER

collaborator

Gustave Roussy, Cancer Campus, Grand Paris

OTHER

lead

Sheba Medical Center

OTHER_GOV

NCT06846736 - ALK Digital Pathology Outcome Predition, Multi Institutional, Restrospective Study | Biotech Hunter | Biotech Hunter